Abstract. Ovarian cancer is one of the most commonly occurring types of cancer and one of the most common causes of cancer-associated mortality in women. Diagnosis of ovarian cancer at an early stage is difficult due to the lack of specific symptoms. In the present study, it is demonstrated that active vitamin D treatment prohibited the proliferation and invasion of ovarian cancer cells, and the expression level of a germ cell specific marker DEAD (Asp-Glu-Ala-Asp)-box helicase 4 (DDX4), which is overexpressed in ovarian cancer, was downregulated by active vitamin D treatment. Knockdown of DDX4 by siRNA could also suppress the invasive ability of ovarian cancer cells. Therefore, DDX4 may be considered as a diagnostic marker of ovarian cancer, and vitamin D may be a candidate drug for ovarian cancer therapy.
Introduction
Ovarian cancer is one of the most common causes of cancer-associated mortality in women (1) . The majority of patients with ovarian cancer are diagnosed at an advanced stage, as there are no reliable symptoms for early diagnosis. Even at advanced stages of disease, signs and symptoms remain nonspecific (2) . Upon diagnosis, ovarian cancer has often already metastasized to the uterus, peritoneum or other organs in the pelvic cavity (3, 4) . Radical surgery and adjuvant chemotherapy are common modes of treatment for ovarian cancer (5, 6) .
Vitamin D has been reported to inhibit the recurrence and distant metastasis of 19 types of cancer, of which ovarian cancer is one (7, 8) . Furthermore, a previous study demonstrated that mortality rates of ovarian cancer are lower in areas with higher levels of ultraviolet-B (UVB) radiation (9) . An association between vitamin D deficiency and the occurrence of ovarian cancer has been suggested (10) .
The germ cell-specific marker DEAD (Asp-Glu-Ala-Asp)-box helicase 4 (DDX4), which is the human ortholog of the Drosophila vasa gene, encodes a member of the DEAD-box family of ATP-dependent RNA helicases (11) . DDX4 is expressed solely in germ cells, including oocytes and spermatocytes, and has been reported to serve a central role in several aspects of germ cell development (11) . A previous study demonstrated that DDX4 is overexpressed in ovarian cancer (12) .
The present study demonstrated that the proliferative and invasive capacities of ovarian cancer cells were suppressed by active vitamin D. Vitamin D treatment downregulated the expression level of DDX4, and knockdown of DDX4 reduced the invasive ability of ovarian cancer cells.
Materials and methods
Cell culture. The ovarian epithelial carcinoma SKOV3 and OVCAR3 cell lines were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Zhejiang Tianhang Biotechnology Co., Ltd., Sijiqing, China) and 1% penicillin-streptomycin (Beyotime Institute of Biotechnology, Haimen, China), and incubated at 37˚C with 5% CO 2 Cell Counting assay. The relative cell number was measured using a CCK-8 assay. Briefly, cells were cultured in 96-well plates at a density of 1x10 3 cells/well for 24 h, then treated with 0, 25, 50, 100, 250 or 400 µl/ml active vitamin D for 72 h. Subsequently, 10 µl CCK-8 dye (Beyotime Institute of Biotechnology) was added to each well, according to the manufacturer's protocol. The plates were read using a microplate reader at a wavelength of 450 nm. Relative cell number was represented by the absorbance value relative to that of the untreated control cells.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted from SKOV3 or OVCAR3 cells using TRIzol (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. cDNA was synthesized using a ReverTraAce qPCR kit (Toyobo Life Science, Osaka, Japan, Japan), according to the manufacturer's protocol. PCR was performed using an ABI PRISM 7500 system (Thermo Fisher Scientific, Inc.), and the thermocycling conditions were as follows: 95˚C for 60 sec, 40 cycles of 95˚C of 15 sec and 60˚C of 60 sec. The primer sequences for DDX4 are as follows: Forward, CCA GAG GGC TGG ATA TTG AA, and reverse, GCC AGT ATT CCC ACA ACG AC. The primer sequences for GAPDH are as follows: Forward, AAT CCC ATC ACC ATC TTC CA and reverse, AAA TGA GCC CCA GCC TTC T. The ΔCq=Cq gene -Cq reference calculation was adopted to scale the relative levels of gene expression, and 2 -ΔΔCq method was used to calculate the fold change of gene expression (13) . qPCR was performed in duplicate for 3 independent groups of treated cells.
Western blotting. SKOV3 and OVCAR3 cells extracts were lysed with mammalian protein extraction reagent (CWBIO, Beijing, China) supplemented with 1% protease inhibitors (CWBIO) at 4˚C for 30 min. The suspension was then centrifuged at 10,000 x g for 10 min at 4˚C. The supernatant was collected and the protein concentration was determined using a BCA protein quantitation kit (Pierce; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Proteins (10 µg) were separated by 12% SDS-PAGE and transferred into nitrocellulose membranes (Merck KGaA, Darmstadt, Germany). The membranes were blocked with 5% non-fat milk in Tris buffered saline with 0.5% Tween-20 for 1 h at room temperature, then incubated with the following primary antibodies overnight at 4˚C: DDX4 (dilution 1:1,000, cat. no. ab13840; Abcam, Cambridge, UK) and GAPDH (dilution 1:1,000, cat. no. AG019-1; Beyotime Institute of Biotechnology, Haimen, China). The membranes were then incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody (dilution, 1:1,000, cat. no. SA00001-2; ProteinTech Group, Inc., Chicago, IL, USA) for DDX4 and anti-mouse for GAPDH (dilution 1:1,000, cat. no. AF0006, Beyotime Institute of Biotechnology) for 2 h at room temperature and visualized by chemiluminescence using an eECL western blot kit (cat. no. CW0049; CWBIO) and western enhanced chemiluminescence substrates (cat. nos. 102030838 and 102030839; Bio-Rad Laboratories, Inc., Hercules, CA, USA). The western blotting results were quantified using ImageJ software (version 1.48; National Institutes of Health, Bethesda, MD, USA).
Transwell invasion assay. The transwell apparatus was assembled using 8-µm pore Transwell inserts (Corning Incorporated, Corning, NY, USA) in 24-well plates. Each insert were coated with 100 µl Matrigel (diluted in PBS, 1:1). A total of 1x10 5 SKOV3 or OVCAR3 cells were seeded onto the insert and cultured with 250 µl RPMI-1640 medium supplemented with 1% FBS, while the lower chambers contained 500 µl RPMI-1640 supplemented with 10% FBS. Subsequent to incubation for 3 or 5 days, the cells in the upper chambers were removed carefully using cotton swabs, and cells that traversed the Matrigel to the lower surface of the insert were fixed using 4% paraformaldehyde at room temperature for 20 min and stained with eosin (0.5%, R20593, Shanghai Yuan Ye Biological Technology Co., Ltd.) (SKOV3 cells) or hematoxylin (D005, Nanjing Jiancheng Bioengineering Institute, Nanjing China, 0.5%) (OVCAR3 cells) alone, both at room temperature for 20 min. Cells were observed and calculated in five random fields using alight microscope (magnification x100).
Statistical analysis. All statistical analyses were performed using GraphPad Prism (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA). The data are presented as the mean ± standard error of the mean. Statistically significant differences between mean values of two groups were identified using unpaired Student's t-test. Statistically significant differences between mean values of ≥3 groups were identified using analysis of variance and Student-Newman-Keuls post-hoc test. P<0.05 was considered to indicate a statistically significant difference. significantly inhibit the proliferation of SKOV3 and OVCAR3 cells, and a further increase in concentration caused a greater inhibitory effect (Fig. 1) .
Active vitamin D inhibits the invasion of ovarian cancer cells.
Active vitamin D treatment reduced the number of SKOV3 or OVCAR3 cells able to migrate to the lower surface of transwell inserts ( Fig. 2A and B) , suggesting that vitamin D could partially block the invasion ability of ovarian cancer cells.
Active vitamin D downregulated the expression of DDX4
in ovarian cancer cells. It has been established that DDX4 is overexpressed in epithelial ovarian cancer and can be used as an ovarian cancer stem cell marker (14) . To assess whether vitamin D affects the expression of DDX4, SKOV3 or OVCAR3 cells were treated with 100 µl/ml active vitamin D for 72 h prior to RT-qPCR and western blot analyses. It was demonstrated that vitamin D treatment downregulated the expression of DDX4 at the mRNA (Fig. 3A) and protein (Fig. 3B ) levels.
DDX4 knockdown inhibits invasion of ovarian cancer cells.
To investigate whether DDX4 could influence the invasion of ovarian cancer cells, several independent siRNAs targeting DDX4 were transfected into SKOV3and OVCAR3 cells individually. The knockdown efficiency was evaluated by RT-qPCR, which demonstrated that transfection with siDDX4-121 or siDDX4-712 could significantly reduce DDX4 expression (Fig. 4) . siDDX4-121-transfected cells were selected for the transwell assay, due to the greater inhibition of DDX4 expression achieved using this siRNA. Invasive cells were stained 3 or 5 days subsequent to siRNA treatment ( Fig. 5A and B) . DDX4 knockdown partially inhibited the invasive ability of SKOV3 and OVCAR3 cells ( Fig. 5A and B) . 
Discussion
Vitamin D was first recognized for its regulatory function in calcium-phosphorus balance (15) . Recently, it has been demonstrated that active vitamin D affects various cellular processes, including proliferation, invasion, differentiation and malignant transformation (8, (16) (17) (18) in multiple types of cancer (18, 19) , including male reproductive system carcinomas and prostate cancer (12) . It has also been suggested that vitamin D could prevent ovarian cancer progression (8) . The present study demonstrated that the proliferative and invasive abilities of SKOV3 and OVCAR3 ovarian cancer cells could be inhibited by active vitamin D. However, the molecular mechanisms of how vitamin D inhibits the proliferation and invasion of ovarian cancer cells remain to be further investigated.
DDX4 is expressed exclusively in the ovaries and testes. The expression level of DDX4 in SKOV3 and OVCAR3 cells was downregulated by active vitamin D at the mRNA and protein level. Knockdown of DDX4 by siRNA partially inhibited the invasion ability of SKOV3 and OVCAR3 cells. It is speculated that vitamin D may inhibit the invasion of ovarian cancer cells through downregulating the expression of DDX4.
In conclusion, vitamin D treatment reduced the proliferation and invasion of ovarian cancer cells. DDX4, which was previously found to be overexpressed in ovarian cancer, was downregulated by vitamin D on the mRNA and protein levels. DDX4 knockdown also inhibited the invasion of ovarian cancer cells. Therefore, the use of vitamin D should be considered as a potential novel therapy for ovarian cancer.
